Xencor, Inc. (NASDAQ:XNCR - Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $13.91 and last traded at $14.12, with a volume of 23914 shares traded. The stock had previously closed at $14.46.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on XNCR. Piper Sandler raised shares of Xencor from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Wells Fargo & Company lowered their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. StockNews.com raised shares of Xencor from a "sell" rating to a "hold" rating in a research report on Thursday. Finally, BMO Capital Markets reaffirmed an "outperform" rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Xencor presently has an average rating of "Buy" and an average price target of $34.38.
Read Our Latest Analysis on Xencor
Xencor Price Performance
The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $977.31 million, a P/E ratio of -4.33 and a beta of 0.75. The company's 50-day simple moving average is $18.39 and its 200 day simple moving average is $20.56.
Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after acquiring an additional 418,040 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Xencor by 2.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock valued at $92,758,000 after acquiring an additional 107,350 shares during the period. Point72 Asset Management L.P. raised its position in shares of Xencor by 147.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company's stock valued at $62,748,000 after acquiring an additional 1,858,440 shares during the period. TCG Crossover Management LLC raised its position in shares of Xencor by 1.0% in the 4th quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after acquiring an additional 25,000 shares during the period. Finally, RTW Investments LP raised its position in shares of Xencor by 317.9% in the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock valued at $55,218,000 after acquiring an additional 1,827,883 shares during the period.
Xencor Company Profile
(
Get Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
